Dr. Leighl continued her presentation on "Highlights in Lung Cancer, 2012" with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a "driver mutation" like an EGFR mutation or an ALK rearrangement.  However, she notes that several new targets that may be especially relevant for patients with squamous NSCLC are becoming the subject of growing clinical research. In addition, one exciting development from 2012 that appears perhaps particularly beneficial for patients with squamous NSCLC is anti-PD1 antibody immunotherapy, an agent now known as nivolumab.  

Here are the video and audio versions of the podcast for this portion of the webinar, along with the associated figures:

[powerpress]

Leighl Highlights in LC 2012 Pt 4 Squam and Anti-PD1 Audio Podcast

Leighl Highlights in LC 2012 Pt 4 Squam and Anti-PD1 Figures

The last portion of her presentation, covering developments in maintenance therapy for advanced NSCLC, will be posted shortly.